PT - JOURNAL ARTICLE AU - Cordeiro, Milena Mendes AU - Malta, Felipe Aguiar Pupo Seabra AU - Gonçalves, Daniela Caetano TI - Mistletoe as a Therapeutic Option in Cancer Patients: a scoping review protocol AID - 10.1101/2023.07.29.23293280 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.29.23293280 4099 - http://medrxiv.org/content/early/2023/07/30/2023.07.29.23293280.short 4100 - http://medrxiv.org/content/early/2023/07/30/2023.07.29.23293280.full AB - Objective This scoping review aims to identify, map and provide an overview of the studies investigating the therapeutic use of Viscum Album L. (mistletoe) in cancer patients. By identifying pivotal patterns and research gaps in the existing literature on Viscum therapy, this review intends to offer valuable insights and supportive information to better inform future research efforts in this field.Introduction Cancer exerts a significant impact on global mortality, posing numerous challenges to public policies. The disease progression and the conventional treatment itself presents multifaceted health adversities to subjects. In response to these complexities, researchers have been exploring non-conventional therapeutic approaches, including phytotherapy. Mistletoe, a widely-used herbal medicine in oncology, is currently undergoing investigation for its potential adjuvant roles in both curative and palliative cancer care.Inclusion criteria We will consider studies that include individuals with cancer, irrespective of participant’s age or cancer type/stage, and who were subjected/exposed to interventions based on or incorporating Viscum album L. The review will consider clinical, quasi-experimental, and analytical observational studies, with no limitations on the time of intervention/exposure, treatment stage or geographic region.Methods This review will follow the methodological guidance of the JBI Manual for Evidence Synthesis for scoping reviews. The searches will be conducted in the following databases: MEDLINE (via PubMed), CENTRAL (via Cochrane Library), Embase (via Elsevier), Scopus, Web of Science Core Collection, CINAHL (via EBSCO), LILACS and SciELO. The search strategy will be adapted to the specificities of each of these databases, using thesaurus terms and synonyms related to the intervention (mistletoe) and the population (cancer), without restrictions on language or date of publication. The search for unpublished studies will be done in Google Scholar, preprint servers (medRxiv and bioRxiv) and trial registry platforms (Clinical Trials and International Clinical Trials Registry Platform), along grey literature in OpenGrey. Initially, eligibility criteria will be screened by two independent reviewers, assessing article titles and abstracts. Following finishing the full reading and inclusion determination, data extraction will be carried out by two independent reviewers. The results will be presented in narrative form and through tables and graphs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study will use ONLY data sources openly available, which can be located at MEDLINE, CENTRAL, Embase, Scopus, Web of Science Core Collection, CINAHL, LILACS and SciELOI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.